Company Overview - Biodesix, Inc. (BDSX) announced a new post-market clinical validation study published in CHEST Pulmonary Journal, reaffirming the performance of its Nodify CDT blood-based lung nodule test [1][4] - The Nodify CDT test is designed to detect cancer-associated autoantibodies, aiding in the identification of potentially malignant lung nodules and helping healthcare providers prioritize further diagnostic evaluations [2][6] Stock Performance - Following the announcement, BDSX shares increased by 2.7%, closing at $1.49, although the stock has lost 24.7% over the past year compared to the industry's growth of 3.9% and the S&P 500's gain of 24.4% [3][4] Market Capitalization and Revenue Estimates - BDSX currently has a market capitalization of $210.9 million, with the Zacks Consensus Estimate for fiscal 2024 revenues at $70.6 million, indicating a growth of 43.7% from fiscal 2023 [5] Study Data and Findings - The study included 447 patients with lung nodules managed conventionally, revealing that 33% of patients with cancerous nodules received a diagnosis more than three months after detection, indicating missed opportunities for early detection [8] - The Nodify CDT test demonstrated high specificity in accurately identifying benign lung nodules, outperforming PET scans, which had more false positives, thus highlighting the test's value as a safer diagnostic tool [9] Industry Prospects - The global lung cancer screening market was valued at $3.55 billion in 2024 and is projected to reach $7.10 billion by 2032, with a CAGR of 9.1% during the forecast period [10] - The market growth is driven by increasing lung cancer incidence due to smoking, technological advancements in screening, and government support for early detection [11]

Core Insights - The article discusses the validation of the Nodify CDT blood-based lung nodule test, reaffirming its performance in detecting lung cancer through a study published in CHEST Pulmonary Journal [1] Company Overview - Biodesix, Inc. is a leading diagnostic solutions company focused on lung disease, offering five Medicare-covered tests for patients with lung diseases [2] - The company’s Nodify Lung Nodule Risk Assessment combines the Nodify CDT and Nodify XL2 tests to evaluate the risk of malignancy in pulmonary nodules, aiding physicians in patient triage [2] Test Performance - The Nodify CDT test measures levels of seven autoantibodies associated with lung cancer, providing a "rule in" test for likely cancerous nodules [1] - In a study of 447 patients, 33% of those with cancerous nodules were diagnosed more than three months after detection, indicating missed opportunities for early diagnosis [1] - The Nodify CDT test demonstrated high specificity, with a low percentage of benign nodules misclassified as high risk, outperforming positron emission tomography (PET) scans which had more false positives [1] Clinical Implications - The study suggests that the Nodify CDT test may serve as a useful adjunct in clinical practice, potentially avoiding delays in treatment for patients with cancer [1] - The findings highlight the inadequacy of relying solely on PET scans for diagnostic decision-making in lung nodule risk assessment [1]

Core Viewpoint - Biodesix, Inc. (BDSX) has experienced significant selling pressure, resulting in a 23% decline in stock price over the past four weeks, but analysts anticipate improved earnings reports in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) for BDSX is currently at 28.65, indicating that the stock may be oversold and could rebound as selling pressure exhausts [5] - The RSI is a momentum oscillator that helps identify potential price reversals, with a reading below 30 typically signaling an oversold condition [2][3] Group 2: Earnings Estimates - There has been a consensus among sell-side analysts to raise earnings estimates for BDSX, resulting in a 2.8% increase in the consensus EPS estimate over the last 30 days [7] - An upward trend in earnings estimate revisions is generally associated with potential price appreciation in the near term [7] Group 3: Analyst Ratings - BDSX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, suggesting a favorable outlook for the stock's performance [8]

Biodesix, Inc. (NASDAQ:BDSX) Q3 2024 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Sung Ji Nam - Scotia Bank Bill Bonello - Craig-Hallum Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to Biodesi ...

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.08, delivering a surprise of 11.11%.Over the last four quarters, the company has surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-3986492 (State or other jurisdictio ...

Exhibit 99.1 Biodesix Announces Third Quarter 2024 Results and Highlights Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, CO, November 1, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. "The Biod ...

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. “The Biodesix team is pleased to report another solid quarter fo ...

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences: Craig-Hallum 15th Annual Alpha Select Conference1x1 MeetingsDate: Tuesday, November 19, 2024Location: New York, NY Wolfe Research Healthcare Conference 20241x1 MeetingsDate: Wednesday, November 20, 2024Loc ...

Biodesix, Inc. (NASDAQ:BDSX) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Chris Brinzey - IR Scott Hutton - CEO Robin Harper Cowie - CFO Conference Call Participants Andrew Brackmann - William Blair Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Biodesix Q2 2024 Earnings Conference Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today. Chris Brinzey, Investor Relations, ...